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Rectal administration of nicomorphine in patients improves biological 
availability of morphine and its glucuronide conjugates
• P .M . Koopm an-Kim enai, T .B . Vree, L .H .D .J . Booij and R. D irksen
Introduction
Nicomorphine (3,6-dinicotinoylmorphine) has been 
introduced as an opioid analgesic both for systemic 
and perispinal use. Although the effectiveness of 
nicomorphine has been established, its action is con­
sidered not to relate to the compound itself. Nico­
morphine is considered to be a 'prodrug7, which 
exerts its analgesic effects through one or several of 
its metabolites [1 2]. The two nicotinoyl ester groups 
increase the lipid solubility and permit chemical and 
enzymatic hydrolysis into 3- or 6-mononicotinoyl- 
morphine and further into morphine. Morphine is 
subsequently glucuronidated at the C3- and expos­
itions, yielding morphine-3-glucuronide and mor- 
phine-6-glucuronide.
In order to measure nicomorphine and its metab­
olites, we developed a sensitive method of analysis 
by means of high pressure liquid chromatography 
(HPLC) with electrochemical and UV detection [3], 
and described the pharmacokinetic behaviour of 
nicomorphine and its unconjugated metabolites 
6-mononicotinoylmorphine (6MNM) and morphine 
[4-6]. Considering the fate of nicomorphine in the 
biological system and the apparent lack of intrinsic 
activities, the conclusion is justified that not the 
parent drug but rather the metabolites cause the 
drug to take effect in man. The serum concen­
tration-time course of nicomorphine and its metab­
olites depends on the route of administration, as 
shown earlier for the unconjugated compounds 
[4-6].
In this study we investigated the pharmacokinetics 
of nicomorphine and its metabolites with their glucu­
ronide conjugates in patients after rectal adminis­
tration. The results of this rectal administration were 
compared to those obtained after intravenous 
administration in order to establish the absolute bio­
availability of nicomorphine and morphine.
Methods
Patients
The study was carried out in 8 healthy patients [class 
Ml, classification of the Association of American Anes­
thesiologists (ASA)], aged 25-50 years, with normal 
body weights. All patients were scheduled to under­
go gynaecological elective abdominal surgery. 
Approval was given by the local Ethics Committee, 
and informed consent was obtained from each 
patient. Excluded were patients with liver or kidney 
dysfunction, known allergic reactions, use of opiates 
or opiate antagonists, or an expected blood loss 
greater than 500 ml during the surgical procedure.
Anaesthesia
All patients were premedicated orally with diazepam
10 mg 1 h before the induction of anaesthesia. An 
intravenous drip cannula (18C) was inserted into a 
suitable arm vein, non-invasive blood pressure moni-
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Abstract
The pharmacokinetics of 30 mg nicomorphine after rectal 
administration with a suppository are described in 8 patients 
under combined genera and epidural anaesthesia. No 
nicomorphine or 6-mononicotinoylmorphine couid be 
detected in the serum, Morphine appeared almost 
instantaneously with a lag-time of 8 min and had a final 
elimination half-life of 1.48 ± 0.48 h. Morphine was 
metabolized to morphine-3-glucuronide and morphine-6- 
glucuronide. These glucuronide conjugates appeared after a 
lag-time of 12 min and the half-life of these two glucuronide 
conjugates was similar: about 2.8 h (P >0.8). The 
glucuronide conjugate of 6-mononicotinoylmorphine was 
not detected. In the urine only morphine and its 
glucuronides were found. The renal clearance value for 
morphine was 162 ml*min-1 and for the glucuronides 
81 mi*min_1. This study shows that administration of a 
suppository with 30 mg nicomorphine gives an excellent 
absolute bioavailability of morphine and its metabolites of 
88%. The lipid-soluble prodrug nicomorphine is quickly 
absorbed and immediately hydrolysed to morphine.
Accepted August 1994.
Table 1 Demographic data of the patiente
toring consisted of finger plethysmography, and 
electrocardiography was commenced. After epidural 
puncture at the L2-L3 level, a catheter for injection of 
bupivacaine was introduced. Subsequently, an intra- 
arterial catheter (20G) was inserted into a radial ar­
tery. A urine catheter was introduced and connected 
to a reservoir.
Epidural anaesthesia was effected by 0.5% bupi­
vacaine with epinephrine including a test dose of
3 ml and a full dose of 11 ml times the body length 
in metres. The level and intensity of the block was 
tested 5 and 10 min after the injection of the full 
dose. Epidural analgesia was maintained by infusion 
of 0.25% bupivacaine, 4-6 mMv1 epidurally. Induc­
tion of general anaesthesia with thiopentone 
(3-4 mg-kg-1) was followed by relaxation with 
vecuronium bromide (0.1 mg-kg-1) and placement of 
an orotracheal tube (xylocain 2% ointment). Mainte­
nance of anaesthesia was obtained with an inhalation 
gas mixture of 67% nitrous oxide in oxygen. Relax­
ation was maintained with vecuronium bromide 
1-2 mg intravenous. Respiration was controlled at an 
end tidal C 0 2 between 4 and 4.5% (vol/vol). Conco­
mitant therapy was noted on the medication form. 
Care was taken to observe that, according to the 
protocol of the study, no opioid analgesic except 
nlcomorphine was used.
The patients received 30 mg nicomorphine 
(Vilan®) as a suppository. Nicomorphine was given 
during maintenance of anaesthesia after the start of 
surgery when the patient's condition was stable.
The demographic data of the patients are listed in 
Table 1.
Dmgs
Nicomorphine, 3-mononicotinoylmorphine (3MNM), 
6-mononicotinoylmorphine (6MNM), morphine, and 
30 mg Vilan® suppositories were obtained from 
Nourypharma (Oss, the Netherlands). Morphine-3- 
glucuronide (M3G) and morphine-6-glucuronide 
(M6G) were obtained from Sigma (St. Louis, USA).
Sampling
Blood samples of 5 ml were taken just before and at 
regular time intervals during and after anaesthesia: 1,
2, 3, 4, 5, 6, 7, 8, 10, 15, 20, 30, 45, 60, 90, 120, 
240, 360, 480 min, 12 h and 24 h after the adminis­
tration of nicomorphine. The samples were centri­
fuged at 3,000 rpm and the serum was stored at 
-20°C until analysis.
Urine samples were taken from the urine catheter 
in the intervals 0-0.5 h, 0.5-1.0 h, 1-2 h, 2-4 h, 
4-6 h, 6-8 h, 8-12 h, 12-18 h, 18-24 h, 24-36 h and 
36-48 h. The total volume was measured and a 
sample (in duplo) was stored at -20°C until analysis.
Sample preparation
To quantify nicomorphine, 6-MNM, and morphine, 
serum was extracted with the Baker-10 extraction 
system (Baker Chemicals, cat.nr. 70180, Deventer,
Patient Gender Age 
(year)
Body
length
(cm)
Body
weight
(kg)
ASA 
class *
A F 45 160 88 1
B F 42 165 70 !
C F 63 175 75 1
D F 30 165 60 1
E F 29 165 63 Í
F F 42 161 55 !
G F 35 176 58 1
H F 49 175 78 1
Mean (±SD) 42 ±11 168 ±6 68 ± 11
* Association of American Anaesthesiologists classification.
the Netherlands) fitted with 1 ml disposable extrac­
tion columns as a cleaning-up procedure. The extrac­
tion columns, packed with cyanopropylsilane 
bonded to silica gel (CN, Baker, cat.nr. 7021-01), 
were conditioned with two column volumes of 
methanol, two column volumes of water, and 1 ml 
500 mmol/l diammoniumsulfate (pH 9.3). Serum 
(0.5 ml), diluted with an additional 0.5 ml of 
500 mmol/l diammoniumsulfate buffer (pH 9.3), was 
brought onto the top of the column. The column 
was washed with 2 ml of 50 mmol/l diammonium­
sulfate (pH 9.3). The sample was eluted with 2 ml 
chloroform + isopropanol (90 + 10, vol/vol). The 
organic phase was evaporated to dryness under a 
mild stream of nitrogen at 37°C, and the residue dis­
solved in 200 |il water. This enabled the simul­
taneous injection of the same sample on two dif­
ferent HPLC systems: a 20 |ii injection volume for 
electrochemical detection (to quantify 6MNM,
3MNM and morphine) and 50 |il for UV detection 
(to quantify nicomorphine). As 3MNM was never 
detected in patients' samples, it was after some time 
omitted from the calibration samples.
Slightly modified conditions were used to quantify 
both morphine glucuronides (M3G and M6G).
Under these conditions morphine could be quanti­
fied simultaneously. The solid phase extraction of 
0.6 ml serum was carried out on 1 ml cyclohexyl 
cartridges (C6H6, Baker, cat.nr. 7212-01). It was 
washed with 2 ml of 50 mmol/l diammoniumsulfate 
(pH 9.3) and eluted with 0.5 ml 0.01 mol/l KH2P04 
buffer (pH = 2.1) containing 11 % acetonitrile.
Urine samples were treated in the same way 
because only morphine and its glucuronides could 
be detected. Because of the higher concentrations 
100 jil urine was extracted and the cyclohexyl 
column rinsed with 5 column volumes ammonium- s
sulfate buffer (50 mmol/l) before the elution with |
I ml 0.01 mol/l KH2P04 buffer (pH = 2.1) containing *1
I I  % acetonitrile could be carried out. §:
rp 
£  _ «
HPLC conditions I
Nicomorphine and its unconjugated metabolites 
3MNM, 6MNM and morphine were determined by 
means of HPLC as previously described [3].
Morphine and its glucuronides were separated on 249
Volume 
16 
Nr. 
6
1
9
9
4
ei Cp-Sper C8 column (Chrompack, Bergen op 
Zoom, the Netherlands). The mobile phase was a 
0.01 mol/l KH2P04 buffer (pH = 2.1) containing 11% 
acetonitrile and 0.4 g*H heptanesulfonic acid. At a 
flow rate of 2 ml-min-1, M3G was detected with a UV 
detector at 210 nm (Spectroflow 773, Separations, 
Hendrik-ldo-Ambacht, the Netherlands) at a reten­
tion time of 2.3 min. Both M6G and morphine are 
electrochemically active and were quantified using 
an electrochemical detector (ESA, Kratos, Rotterdam, 
the Netherlands) equipped with an analytical cell 
(Model 5010). The detector 1 potential was 0.3 V in 
order to minimize interfering peaks and the 
detector 2 potential was set at 0.4 V. The retention 
times were 2.8 min and 3.5 min for M6G and mor­
phine, respectively.
Recovery and reproducibility
The calibration curves were prepared by adding a 
variable quantity of stock solution to blank serum or 
urine. The calibration samples for the determination 
of nicomorphine, 6MNM, 3MNM and morphine 
were prepared separately for electrochemical and UV 
detection. The calibration graphs were linear for 
morphine in concentrations ranging from 2 to 
300 ng.mH (r = 0.9875), for 6MNM and 3MNM in 
concentrations ranging from 15 to 300 ng-mH 
(r = 0.9915 and 0.9810, respectively) and for nico­
morphine concentrations ranging from 70 to 
800 ng*mH (r = 0.9965). After extraction of patient 
samples, the sample has a volume of 200 \i\. This 
enables injection of the same sample simultaneously 
on both HPLC systems; 20 ¡at for electrochemical 
detection and 50 jul for UV detection. The quanti­
tation limit in serum for morphine is 2 ng.mH, for 
6MNM 10 ng.mH, for 3MNM 30 ng.mH, and for 
nicomorphine 40 ng-mH.
For the measurement of M3G, M6G and mor­
phine, the calibration samples contained all three 
compounds. In serum all calibration graphs were 
linear. For M3G the concentrations ranged from 25 
to 580 ng-mH (r = 0.9882), for M6G from 5 to 
100 ng.mH (r = 0.9892) and for morphine this 
range was from 2 to 90 ng.mH (r = 0,9753). The 
quantitation limit is 25 ng*mH for M3G, 5 ng.mH 
for M6G and 2 ng-mH for morphine. In urine also all 
calibration curves were linear. The ranges and corre­
lation coefficients are 4-20 ¡ig-mH for M3G 
(r = 0.9988), 1-7 jig«mH for M6G (r = 0.9997) and 
1-6 (ng*mH for morphine (r = 0.9996). The .quanti­
tation limit is 1 jig-mH for M3G and 0.2 jig*mM for 
M6G and morphine.
The reproducibility was approximately 5% for the 
concentration ranges of all the compounds men­
tioned above.
The recoveries in the cyanopropyl extraction pro­
cedure for nicomorphine, 6MNM, 3MNM and mor­
phine were 69%, 96%, 91% and 87%, respectively. 
The recovery percentages in the cyclohexyl extrac­
tion procedure for M3G, M6G and morphine were 
96%, 97% and 97%, respectively.
Procedure for the detection of glucuronides
Deglucuronidation was carried out with p-glucuroni- 
dase type H-2 from Helix pomatia (G-0876, Sigma, 
St. Louis, USA). A sample of 100 jil was mixed with 
25 jil p-glucuronidase type H-2 and 125 |il buffer
(0.2 mol/l sodium acetate pH = 5.0). The reaction 
was carried out overnight and was stopped by the 
addition of 800 \x\ 500 mmol/l diammonium sulfate 
buffer (pH = 9.3), followed immediately by the 
extraction procedure. Both morphine glucuronides 
are commercially available, and calibration samples, 
with a known amount of glucuronides, were sub­
jected to this reaction. Under these conditions the 
glucuronides completely disappeared from the chro­
matogram, while there was an equal molar increase 
in morphine concentration. This deglucuronidation 
was carried out if the amount of M6G was not suffi­
cient to be weighed accurately. In patient samples 
this procedure was used to determine the presence 
of morphine-3,6-diglucuronide. If this diglucuronide 
was present, an unknown peak had to disappear 
from the chromatogram and the increase in mor­
phine concentration had to be more than that 
accounted for by the former presence of M3G and 
M6G.
Pharmacokinetics
All pharmacokinetic calculations were carried out 
using the computer package MW/Pharm® obtained 
from Mediware (Groningen, the Netherlands) [4]. 
This is a non-linear curve-fitting program, based on 
the least-square method. Morphine was fitted as an 
extravascular administration with a lag time and a 
two-compartment elimination model. M3G and 
M6G were fitted as an extravascular administration 
with a lag time and a one-compartment elimination. 
The coefficient of determination (r2) shows what the 
fit to the serum data looks like. The area under the 
serum concentration-time curve (AUC0. J  was calcu­
lated from the data of the fitted curve and extrapo­
lated to infinite time. This could be done because the 
AUC of the observed data and the AUC of the fitted 
curve correlated well: r(M3G) = 0.9971, r(M6G) = 
0.9907 and r(morphine) = 0.9987. The maximum 
serum concentration Cmax (ng-mM) occurs at fmax (h). 
The renal clearance CLr was calculated as jug ex- 
creted/AUC0.M. As the parent compound was not 
detected in serum, pharmacokinetic parameters such 
as CL and V% could not be calculated.
Statistics
P values were calculated using analysis of variance 
according to standard procedures. Statistically signifi­
cant differences are assumed at P < 0.05.
Results
Figure 1 shows representative serum concentration­
time curves of all metabolites in a patient after a rec­
tal dose of 30 mg nicomorphine. The parent com­
pound nicomorphine nor the metabolite 6MNM or 
3MNM were detectable in the serum. Morphine 
appeared after a lag time of 10 min, reached a Cmax 
of 52 ng.mH at tmax of 34 min and was eliminated 
with a final half-life (t1/2p) of 1.7 h. M3G and M6G 
appeared in the serum about 17 min after adminis­
tration and reached their maximum concentration 
after 1.3 h. They were eliminated with almost iden­
tical half-lives of 3.89 h (M3G) and 3.47 h (M6G).
The renal excretion rate-time profiles of this 
patient are also shown. M3G was the main metab­
olite in the urine. Of the dose administered, 31.8%
plasma conc. ug/ml 
rena! excr. rate ug/min
10 0
1 0
30 mg Nicomorphine supp.
r
i
i
it
t
t
. J
mm
M-3-gluc 31.8%
M-6-gluc 7.1 %
M 3 .4 %
0 . 0 1
0 . 0 0 1
' ' - a .
M-3-gluc 
11/2 3.9 h
M-6-gluc
ti/2 3.5 h
t1/2 1.7 h
i—i—i—r
8  1 0
t r - i i
12 14 h
A Figure 1
The serum concentration-time curves and the renai 
excretion-time curves for a patient after a rectal dose of
30 mg nicomorphine as a suppository
appeared in the urine as M3G, 7.1% as M6G and 
3.4% as morphine.
Table 2 summarizes the pharmacokinetic par­
ameters of nicomorphine and its metabolites in the
8 patients. The ty2p of morphine (1.48 ± 0.48 h) 
differed significantly from those of M3G and M6G 
(P < 0.015). The tV2p of M3G (2.80 ± 1.08 h) and 
M6G (2.71 ± 1.05 h) were similar (P >0.8), The renal 
clearance of morphine (162 ± 70 ml*min~1) differed 
significantly from that of M3G (71 ± 19  mUmin"1) 
and M6G (91 ± 41 ml-min-1) (P < 0.0035). The renal 
clearance values of both glucuronides were similar 
(P = 0.23).
Discussion
Metabolism
When given intravenously or intramuscularly, nico­
morphine is quickly metabolized to the metabolites 
6MNM and morphine with a half-life of 1 min [5-7]. 
No 3MNM was detected. This study shows that after 
rectal administration, nicomorphine was not present 
in serum, nor could the metabolites 6MNM and 
3MNM be detected in the serum. Apparently the 
rate of hydrolysis in the alkaline colon was high. 
Morphine was found in the serum 8 min after ad­
ministration. Its terminal elimination half-life was
itions. The two glucuronide conjugates were present 
in plasma [8-10] and urine [11], M3C has been 
shown to be a potent functional antagonist of mor­
phine and M6G antinociception after intracerebro- 
ventricular administration to rats [12 13]. The conju­
gate M6G contributes to the analgesic effect [14 15]. 
The final serum half-life of morphine varied between 
1.03 and 2.34 h (mean 1.48 h). In one patient (H) a 
one-compartment model fitted best as can be seen 
from the fact that both elimination half-lives (t]i2a 
and ty2\]) were identical. The apparent terminal elimi­
nation half-life of morphine is shorter than the half- 
life of both glucuronides: mean 2,80 h for M3G and 
2.71 h for M6G. Hanna et al, [16] found that M6G 
declined in parallel with morphine in the terminal 
phase after administration of morphine. As no atten­
tion was paid to M3G, no conclusions can be drawn 
about the competing pathways. It is important to 
measure M3G, because if present in larger concen­
trations it can be a source of morphine in the termi­
nal phase, due to the enterohepatic circulation and 
deglucuronidation in the intestine [17-19]. Unfortu­
nately, our quantitation limit is not low enough to 
visualize the fact that after administration of nico­
morphine (30 mg), morphine, M3G and M6G are 
running parallel in the terminal phase. Long-lasting 
steady-state levels of morphine and its glucuronides 
are reported in patients with kidney failure [20 21]. 
The terminal phase of morphine is formed out of the 
glucuronides and runs parallel to both glucuronides, 
as excellently shown by D'Honneur et ai. [22]. De­
glucuronidation of the morphine glucuronides in the 
intestine, and the enterohepatic recirculation govern 
the terminal half-life of morphine [23-25], which is 
clearly visible after an oral dose of 30 mg morphine 
sulphate [22; Guelen PJM, personal communication].
Biological availability
After intravenous administration of 30 mg nico­
morphine the mean total sum of the areas under the 
serum concentration-time curves is 7.8 jimol-h-H 
(AUCQ.M of nicomorphine + 6MNM + morphine + 
M3G + M6G) [26], which is in the same order of 
magnitude as after rectal administration of 30 mg 
nicomorphine: 6.9 jimoUh*M (AUC0.;c of morphine + 
M3G + M6G). Thus the biological availability of nico­
morphine from a suppository is 0%; the biological 
availability of this pharmaceutical formulation, 
expressed as the morphine bioavailability (AUC0.W of 
morphine + M3G + M6G) after administration of the 
suppository is 88% compared to the intravenous 
administration. The rectal administration of mor­
phine in a suppository results in a large variation in 
bioavailability (31-72%) relative to an extravascular 
administration. The absolute biological availability of 
morphine alone was 53.3 ± 17.8% as reported by 
Jonsson et al. [27].
Reported variation in bioavaiiability is in part due 
to the analytical methodology and the analytes 
measured. Morphine biological availability in the 
literature is expressed relative to an intramuscular 
administration [28 29], oral administration (30%) 
[30 33], rectal administration of a tablet (30-70%) 
[32] or other rectal formulations [33].
1.48 ± 0.48 h. The rate of the morphine formation The present study shows that administration of a
must be due to enzymatic reactions in the rectum. 
Morphine is glucuronidated at the C3 and C6 pos-
suppository with 30 mg nicomorphine gives an 
excellent absolute biological availability of morphine
T a b le  2 Pharmacokinetic parameters of the metabolites o f nicomorphine after a 30 mg suppository
Parameter* Patient ____________________________________
A B C D
Morphine 
Cma* (ng-mH) 37 49 52 48
n^ux (fr) 0.72 0.52 0.56 0.47
AUC0.„ (ng-h-H) 77 71 103 83
Lag time (h) 0.16 0.23 0,16 0,08
/2abs (h) 0.37 0.15 0.22 0.20
t]j2u. (h) 0.35 0.15 0.22 0.20
(h)9 2.34 1.04 1.71 1.08
X2 0.9699 0.9700 0,9816 0.9825
C lr (ml-min-1) 82 135 95 122
% in urine 2.2 3.3 3.4 3.5
Morphine-3-glucuronide 
Cmax (ng*mH) 502 371 455 520
r^nax (M 1.37 1,45 1.28 0,79
AUC0.W Otg.h.H) 4,147 2,096 3,078 2,285
Lag time (h) 0.21 0.16 0.22 0,11
tlttabs (h) 0.26 0,39 0,25 0,16
¿1/2 (h) 4.84 2.87 3.89 2.53t
r2 0.9898 0.9912 0,9984 0,9617
CL (ml-min“1) 40 77 48 64
% in urine 36.1 35.0 31,8 31.5
Morphine-6-giucuronide 
Qtax (ng-mH) 79 58 73 99
tmax (h) 1.20 1.77 1,40 0.71
AUC,)  ^(pg-h-M) 481 446 455 468
Lag time (h) 0.42 0.04 0.32 0.24
tyiabs (h) 0.17 0.51 0.27 0,09
12 O1) 3.65 3.90 3,47 2,91
r2 0,9830 0.9757 0.9973 0.9883
CLr (mNmin-1) 67 76 72 69
% in urine 7.0 7.3 7.1 7.0
E F €  H Mean (±SD)
4
45 32 66 27 45 ±12
0,28 0.62 0.48 0.55 0.53 ±0.13
55 47 114 31 73 ±28
0,08 0.12 0.09 0,12 0.13 ±0.05
0.12 0,32 0.23 0.30 0,24 ± 0,09
0,12 0.35 0.23 0.30 0.24 ± 0.09
1,57 1.03 1.61 0,30 1.48 ± 0.48
0,9721 0.8645 0.9657 0.9230
129 240 229 261 162 ±70
2.5 3.7 7.3 2.8 3.6 ± 1.6
757 379 608 514 513 ±125
0.73 1.21 1,02 1,64 1.19 ±0.32
2,431 1,733 2,836 2,303 2,614 ±746
0.11 0,14 0.15 0.14 0.16 ± 0.04
0.17 0.33 0.23 0.69 0,31 ±0,17
1,74 2.29 2.55 1.67 2.80 ± 1.08
0.9721 0,9888 0.9923 0.9100
78 91 78 91 71 ±19
40.8 34,2 47.5 45.1 37.8 ±6.0
151 53 73 89 84 ±31
0.80 1.38 1,25 0.83 1.17 ±0.36
490 184 415 305 406 ±107
0,17 0.09 0.16 0.44 0.24 ±0.15
0.17 0.89 0,29 0.08 0.31 ±0.27
1,74 0.89 3,07 2.08 2.71 ±1,05
0,9743 0.9791 0 .9622 0.9991
63 176 74 130 91 ±41
6.6 7,0 6.6 8.6 7.2 ±0.6
*Cmax: maximum serum concentration; tmax: time at which Cmax occurs; AUC0_M: area under the serum con­
centra tion-t ime curve; lag time: time after which the compound appears in the serum; /2abs: absorption 
halMife; ty2(lif  half-life of elimination of the different phases; r2: coefficient of determination of the fitted 
curve; CL,-: ¡ig excreted/AUC0^ ; % in urine: total amount (% molar) recovered in the urine as percentage 
of the dose of the administered compound,
and its metabolites of 88%. The lipid-soluble pro­
drug nicomorphine is rapidly absorbed and imme­
diately hydrolysed to morphine.
Renal clearance
In the urine only morphine and its conjugates were 
present. The renal clearance (CLr) of the metabolites 
is listed in Table 2. There are large inter-individual 
differences, but it is remarkable that the renal 
clearance of morphine (mean 162 ml*min~1) is higher 
than that of both glucuronides (mean 81 ml-min-1). 
This can be explained by the different excretion 
mechanisms: morphine is cleared via the organic 
cation transport system, while the glucuronides are 
cleared by glomerular filtration and tubular reabsorp­
tion [34 35]. These results are comparable with our 
results after intravenous administration: 200 ml-min'1 
(morphine) and 115 ml-min-1 (M3G and M6G), 
respectively [25]. As van Crugten et ai. [36] de­
scribed, it is an unusual phenomenon that glucuro- 
nide metabolites, which are larger and less lipophilic 
than morphine, undergo net tubular reabsorption. 
However, Carrupt et ai, [37] described that M6G and 
to a lesser extent M3G are far more lipophilic than 
predicted and in fact are not much less lipophilic 
than morphine itself. It has been reported that the 
clearance of morphine, apart from enterohepatic 
cycling, is influenced by several factors, e.g. age, race 
and also variation in hepatic blood flow during peri- 
and postoperative situations [38]. There is no evi­
dence or indication about the existence of a mor- 
phine-3,6-diglucuronide [39].
Conclusion
This study shews that administration of a suppository 
with 30 mg nicomorphine gives an excellent absol­
ute biological availability of 88% of morphine and its
metabolites. The lipid-soluble prodrug nicomorphine 
is rapidly absorbed and immediately hydrolysed to 
morphine. The action of rectaliy administered nico­
morphine must be explained by the formation of 
two (active) metabolites: morphine and morphine-6- 
glucuronide. The kinetics of these metabolites after 
the rectal administration of nicomorphine finally 
resemble those after morphine administration.
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